Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ: REGN · Real-Time Price · USD
580.41
+14.44 (2.55%)
At close: Aug 15, 2025, 4:00 PM
579.00
-1.41 (-0.24%)
After-hours: Aug 15, 2025, 7:57 PM EDT
Regeneron Pharmaceuticals Revenue
Regeneron Pharmaceuticals had revenue of $3.68B in the quarter ending June 30, 2025, with 3.62% growth. This brings the company's revenue in the last twelve months to $14.21B, up 5.38% year-over-year. In the year 2024, Regeneron Pharmaceuticals had annual revenue of $14.20B with 8.27% growth.
Revenue (ttm)
$14.21B
Revenue Growth
+5.38%
P/S Ratio
4.36
Revenue / Employee
$940,964
Employees
15,106
Market Cap
60.18B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 14.20B | 1.08B | 8.27% |
| Dec 31, 2023 | 13.12B | 944.30M | 7.76% |
| Dec 31, 2022 | 12.17B | -3.90B | -24.26% |
| Dec 31, 2021 | 16.07B | 7.57B | 89.14% |
| Dec 31, 2020 | 8.50B | 1.94B | 29.58% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
REGN News
- 4 days ago - Regeneron: EYLEA's Decline Is Masking A Deep Value Opportunity - Seeking Alpha
- 11 days ago - These Analysts Increase Their Forecasts On Regeneron Pharmaceuticals After Better-Than-Expected Earnings - Benzinga
- 14 days ago - Regeneron: Rapidly Decreasing Importance Of Eylea - Seeking Alpha
- 14 days ago - Regeneron Pharmaceuticals, Inc. (REGN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 14 days ago - Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges - WSJ
- 14 days ago - US FDA declines to approve Regeneron's blood cancer therapy for second time - Reuters
- 14 days ago - Regeneron beats second-quarter results estimates on Dupixent sales boost - Reuters
- 14 days ago - Regeneron Reports Second Quarter 2025 Financial and Operating Results - GlobeNewsWire